Tardyfer

Quick links to important sections

Tardyfer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tardyfer

Property Description
Active Ingredient Ferrous sulfate (divalent iron, Fe²⁺)
Form Prolonged-release tablet (oral)
Pharmacological Class Antianemic preparation, Iron replacement therapy
Common Use Management of iron deficiency states
Origin Synthetic inorganic salt formulation

Tardyfer is classified as an antianemic preparation and is a therapeutic agent used for iron replacement therapy. Its primary function is to deliver iron to the body to correct or prevent iron deficiency states, which are essential for the synthesis of hemoglobin. The key mechanism involves providing iron for red blood cell formation, which is crucial for oxygen transport throughout the body.

What Type of Medicine is Tardyfer?

Tardyfer is not a general nutritional supplement but a medicine targeted against a specific mineral deficiency, a distinction clinically recognized in medical practice. The medication's active ingredient is ferrous sulfate, a highly utilized and generally well-absorbed synthetic inorganic salt that supplies divalent iron (Fe²⁺). The use of ferrous sulfate as a core component in oral iron therapy is based on its established efficacy in restoring iron levels. This therapy is typically considered in scenarios such as managing low iron levels in pregnant women or in individuals with chronic dietary deficiencies.

Composition and the Prolonged-Release Tablet Form

The composition of Tardyfer is centered on the administration of ferrous sulfate via an oral, prolonged-release tablet. This dosage form is engineered to utilize sustained release principles to manage the timing and location of iron delivery within the gastrointestinal tract. This design is a key differentiating factor from traditional, immediate-release iron salts; its structure ensures the iron is released gradually, which is intended to facilitate more efficient gastrointestinal absorption and potentially improve patient tolerability. The sustained release mechanism ensures the iron is gradually available for uptake in the small intestine.

General Purpose: Why is Tardyfer Used?

The general purpose of using Tardyfer is to promote the restoration of iron reserves and manage conditions arising from low iron, such as anemia. By providing a stable source of absorbable iron, the medication directly supports the body's ability to synthesize hemoglobin. Replenishing these stores is essential for reversing the biological impact of iron deficiency and maintaining adequate oxygen transport throughout the tissues, which addresses the systemic fatigue and weakness often associated with depleted iron reserves.

Regulatory References

  1. Ferrous Sulfate Label - DailyMed (NIH)
  2. Ferrous Sulfate Drug Labeling - FDA
  3. Ferrous Sulfate Monograph - USP-NF
  4. European Public Assessment Report (EPAR) - EMA

What side effects are possible with Tardyfer?

Possible Side Effects and Safety Information

The safety profile of Tardyfer (ferrous sulfate) is defined by officially documented adverse reactions and strict safety limitations, as formalized by government regulatory agencies.


Frequency-Classified Adverse Reactions

The majority of documented effects involve the Gastrointestinal Disorders system-organ class.

Frequency Adverse Reaction
Common (1 to 10 users in 100) Constipation, Diarrhea, Abdominal distension, Abdominal pain, Feces discolouration (black stools), Nausea.
Uncommon (1 to 10 users in 1,000) Swelling of the larynx (Laryngeal oedema), Abnormal feces, Vomiting, Indigestion (Dyspepsia).
Not Known (Cannot be estimated) Hypersensitivity reactions (e.g., Urticaria, Rash), Esophageal ulceration, Esophageal stricture, Colonic pigmentation (Melanosis coli).

Serious Adverse Reactions and Safety Restrictions

Official labels highlight critical risks and mandatory restrictions:

  • Serious Risks: These include potentially life-threatening iron intoxication/overdose, particularly in children, and severe localized effects such as Esophageal ulceration.
  • Population-Specific: A key regulatory concern is the extreme danger of accidental poisoning in children; iron supplements must be kept out of their reach.
  • Contraindications: The medicine must not be used if there is known hypersensitivity, or in conditions involving iron overload (such as haemochromatosis), or in certain types of non-iron deficiency anemia (such as haemolytic anemia).
  • Exposure Patterns: Colonic pigmentation (Melanosis coli) has been reported with prolonged, long-term use. The degree of iron intoxication is related to the dose ingested in cases of overdose.

This official information structures the understanding of risks by separating the high probability of expected digestive issues from the low, but critical, probability of serious adverse events and strict usage limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overdose manifestations and emergency actions is derived strictly from government regulatory documentation.

Category Official Regulatory Documentation
Documented Overdose Presentations Initial signs of overdose typically include severe gastrointestinal toxicity such such as vomiting, nausea, abdominal pain, diarrhea, and potentially bloody stools or hematemesis. Systemic distress may present as lethargy, dizziness, and pallor [NIH MedlinePlus on Iron Overdose].
Physiological Systems Affected Overdose is documented to affect the Gastrointestinal system, Cardiovascular system (leading to hypotension and shock), Central Nervous System (coma, seizures), Hepatic system (necrosis), Renal system (failure), and the metabolic system (metabolic acidosis) [SmPC for Ferrous Sulfate].
Dose-related or Exposure-related Factors Ingestion exceeding 60 mg/kg of elemental iron is associated with a high risk of severe toxicity and death. Iron overdose is a leading cause of fatal poisoning in young children (under the age of six) [FDA Labeling on Ferrous Sulfate].
Emergency-Response Statements In case of any suspected overdose, immediate medical attention must be sought, or the poison help line must be contacted. Deferoxamine is documented as the specific iron chelating agent indicated for severe intoxication [NIH MedlinePlus on Iron Overdose].

Overdose Classifications (High-Level)

Category Official Regulatory Documentation
Severity Classification Overdose can result in life-threatening systemic toxicity, leading to shock, coma, seizures, hepatic necrosis, and is associated with a fatal outcome [SmPC for Ferrous Sulfate].
Overdose-Context Constraints Required monitoring includes the measurement of serum iron levels (especially 4–6 hours post-ingestion) to guide treatment and an abdominal X-ray (AXR) to detect retained prolonged-release tablets [SmPC for Ferrous Sulfate].

Connection to the overall overdose profile: The regulatory profile mandates immediate action for any suspected overdose due to the rapid progression from initial gastrointestinal signs to severe systemic toxicity and potential fatal outcomes. This severity is specifically noted to be high in children. The official response includes procedures like gastric lavage and the use of the specific antidote, Deferoxamine, for severe cases, underscoring the urgency of the regulator-mandated guidance to seek immediate medical help.

Therapeutic Uses of Tardyfer

Tardyfer (Ferrous sulfate) is an established antianemic preparation whose primary therapeutic role is focused on the management and prevention of iron deficiency states and is used for Iron Deficiency Anemia (IDA). This therapy is relevant as it addresses conditions where blood tests confirm a quantifiable depletion of the body’s iron reserves.

The primary goal is to replenish iron stores, supporting the body's essential oxygen-carrying function. The medication is commonly used to help manage the symptom clusters that create noticeable physiological strain, such as chronic systemic fatigue, profound weakness, and a reduction in physical endurance.

The medication is relevant for managing symptomatic manifestations in conditions such as nutritional deficiencies, chronic blood loss (e.g., heavy menstrual bleeding), and periods of high physiological demand during pregnancy. By replenishing iron, the medication supports the easing of these energy-related symptoms, which may contribute to improved day-to-day comfort.

“This support may assist with maintaining functional stability and contributes to easing the overall symptom load.”


Quick Fact: Relief for Systemic Fatigue

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia on Iron Deficiency Anemia

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tardyfer

The eligibility for Tardyfer is defined by official regulatory documentation, primarily based on the patient's iron status, age, and existing medical conditions.

Eligibility Scope Population/Condition Regulatory Status
Populations for whom use is allowed Adults and Adolescents (typically aged 12 years and over). Permitted for use.
Pregnant and Lactating Women Permitted for use for iron deficiency management.
Populations for whom use is contraindicated Iron Overload Syndromes (Haemochromatosis/Haemosiderosis). Absolute contraindication.
Non-Iron Deficiency Anemias (e.g., Haemolytic anaemia). Absolute contraindication.
Concomitant Parenteral Iron or Repeated Blood Transfusions. Absolute contraindication.

Age-Related Eligibility Rules The prolonged-release tablet formulation is not recommended for children under 12 years due to formulation restrictions. Use in older adults is permitted, but requires careful evaluation if they have difficulty swallowing (dysphagia) because of the formulation’s nature.

Condition-Specific Eligibility Rules Patients with active peptic ulcer, ulcerative colitis, or regional enteritis are formally contraindicated from using this medicine. Caution is advised for individuals with a history of these or other inflammatory bowel conditions.

What should I know about interactions with other medicines?

The use of Tardyfer is formally contraindicated with any parenteral iron preparations (injectable or intravenous iron) according to regulatory labeling.

The principal interaction pattern is pharmacokinetic interference via cation chelation, where the divalent iron ion ( Fe^2+) binds to various co-administered medications in the gastrointestinal tract. This binding results in a significant reduction in the systemic exposure of the affected drug.

This interference affects the absorption of several medicinal categories, including quinolone antibiotics (e.g., Ciprofloxacin), tetracycline antibiotics, L-thyroxine (thyroid hormone), and anti-Parkinsonian agents such as Levodopa and Methyldopa. The systemic exposure of osteoporosis treatments, including Bisphosphonates, and the anti-rheumatic agent D-Penicillamine, is also officially reduced by this mechanism.

To counter reduced exposure, regulatory documents mandate Administration Timing Requirements. For instance, iron must be separated from quinolone antibiotics by at least two hours before or six hours after the antibiotic. Other agents like L-Thyroxine, Levodopa, Antacids, and mineral supplements require a separation of at least two hours to prevent absorption interference.

A pharmacodynamic reinforcement effect is noted with Salts of Salicylic Acid (NSAIDs), where concurrent intake may increase the irritating effect on the gastrointestinal mucous membrane. Furthermore, Tardyfer's absorption is reduced by Dietary and Supplemental Absorption Reduction from substances including tea, coffee, dairy products, and certain herbal products.

Mechanism of Action

The action of Tardyfer is defined by essential nutrient replacement, where it supplies the body with divalent iron ( Fe^2+) to engage and support fundamental biological synthesis pathways.


Gastrointestinal Uptake and Delivery System

This domain covers the movement of the Fe^2+ substrate into the body, focusing on the specific transporter proteins it engages in the small intestine, such as Divalent Metal Transporter 1 (DMT1) and Ferroportin. The specialized prolonged-release formulation facilitates the continuous presentation of iron, maximizing the opportunity for absorption and transfer via transferrin into the systemic circulation. This crucial step determines the overall quantity of iron transferred into the systemic circulation for the body's internal processes.


Heme Synthesis and Erythropoiesis Pathway Engagement

The transported iron is delivered to the bone marrow, where it acts as the necessary core component for the synthesis of heme, the prosthetic group of hemoglobin. By providing this substrate, the mechanism supplements the material required for effective erythropoiesis (red blood cell production). This mechanistic cascade increases the total concentration of functional hemoglobin in the blood, which governs the oxygen-carrying capacity of the circulation.


Addressing Mechanistic Constraints

The replacement mechanism is subject to natural biological constraints, most notably the regulatory action of the peptide hepcidin. Elevated levels of hepcidin, often seen during inflammation, inhibit the ferroportin transporter, functionally blocking the export of absorbed iron from the intestinal cells into the bloodstream. This limitation defines why the mechanism is subject to override by the regulation of the systemic iron status.

Dosage and Administration Information

How to Use Tardyfer — Administration Guidelines

This section outlines the administration instructions for Tardyfer (a modified-release oral iron preparation). These guidelines describe the standard procedures for the use of this medication.

Administration Scope

Field Instruction
Route of Administration The medication must be taken orally (by mouth).
Dosing Schedule Standard adult dosing is typically 1 to 2 tablets daily. Dosage is adjusted based on the specific iron deficiency or prophylaxis regimen outlined by the prescribing information.
Timing in Relation to Meals Tardyfer is generally recommended to be taken before or during a meal. While food may slightly decrease absorption, taking it with meals often improves gastrointestinal tolerance.
Missed-Dose Rule If a dose is missed, patients should not take a double dose to compensate. Continue with the next scheduled dose at the regular time.

Procedural Instructions

Special Procedural Conditions:

The tablet is a modified-release formulation and must be swallowed whole with a glass of water. Patients should not suck, chew, or crush the tablet. Crushing the tablet can destroy the modified-release mechanism, leading to the rapid absorption of a high dose of iron.

Age-Group Administration Rules:

Specific dosing regimens are provided for populations such as pregnant women (often one tablet daily for prevention or treatment) and children, where the dose must be carefully adjusted based on body weight or age as outlined in the prescribing information.

Recent Clinical Evidence

Research evidence / Overview of studies for Tardyfer

Evidence for use in Treating Iron Deficiency Anemia

This section will summarize the core evidence base, including the types of Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated the delivery of oral iron for this primary clinical indication.

Research related to Tardyfer’s active ingredient, ferrous sulfate, was studied for iron delivery in individuals with Iron Deficiency Anemia (IDA) across many years. Studies explored this use primarily through short- to intermediate-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Research examined primary outcomes related to biomarker shifts, focusing on changes in laboratory measurements like Hemoglobin (Hb) and Serum Ferritin, which reflect the body's iron stores. Data show patterns related to increases measured in Hemoglobin and Ferritin levels in the observed populations. The evidence largely relies on measuring these levels—known as surrogate markers—which reflect the biological state but are not direct measures of long-term health or functional capacity.


Research on the Prolonged-Release Formulation

This section will detail the specific clinical and pharmacokinetic studies that examined the design of the prolonged-release tablet, focusing on the research objectives related to gradual iron delivery and the measurement of gastrointestinal tolerability compared to standard iron salts.

Research on the prolonged-release tablet was studied for its impact on how the body absorbs iron and how patients report their experience. Studies explored outcomes related to systemic or functional imbalance, such as gastrointestinal tolerability, a key factor in how patients continue with oral iron therapy. Findings described different patterns in the reported frequency and type of gastrointestinal events when comparing this delivery mechanism to immediate-release iron salts in the observed populations. While research provides insight into short-term changes in tolerability, data are still emerging regarding the overall long-term impact of this specific prolonged-release design on sustained adherence compared to other iron formulations.


Evidence for Iron Deficiency in Pregnancy

This section will outline the dedicated research that was studied for iron supplementation in pregnant populations, focusing on the measures used in trials for both the treatment of existing anemia and the strategies for prophylaxis.

Iron supplements was evaluated in pregnant women through numerous RCTs and subsequent systematic reviews. Research examined the use in women with established IDA and in those where iron was studied for prophylaxis (prevention). Trials reported measurements of changes in iron status and patterns in the incidence of anemia at term when comparing groups in iron-deficient women. Regulatory reviews note that data are still emerging or insufficient to fully assess the benefits and harms of routine iron supplementation for pregnant individuals who are asymptomatic and not iron-deficient at the start of their pregnancy.

Key Studies & References

  1. Tolerability of different oral iron supplements: a systematic review (Cancelo-Hidalgo et al.)
  2. Antenatal iron supplementation (World Health Organization - WHO Guideline)

Frequently Asked Questions (FAQ)

Common questions about Tardyfer (FAQ)


Q: Does Tardyfer cause dark stools or changes in urine color?

According to the official product information, Tardyfer can cause changes in the color of stools, typically making them appear dark or black. This is a common effect of iron supplementation. While often expected, it's always best to discuss any changes with a healthcare provider. There is no mention in the regulatory documents about Tardyfer causing changes in urine color.


Q: Is Tardyfer suitable for people with Celiac disease (gluten-free)?

Regulatory documents state that Tardyfer film-coated tablets do not contain gluten. This ingredient absence makes them generally suitable for people with Celiac disease or those following a gluten-free diet, based on the ingredients listed in the official product information.


Q: Can Tardyfer be taken with food, or must it be taken on an empty stomach?

Official product information indicates that Tardyfer is generally administered before or during meals. The product label specifies that the tablet should be swallowed whole with a glass of water. For specific guidance on timing relative to meals, the detailed product information should be consulted.


Q: Is Tardyfer safe to use during pregnancy and while breastfeeding?

According to official information, Tardyfer can be used during pregnancy and while breastfeeding when a healthcare provider has determined an iron deficiency is present. Regulatory information specifies that use during pregnancy and breastfeeding must occur under the supervision of a healthcare professional.


Q: What is the key ingredient in Tardyfer?

The key active ingredient in Tardyfer is ferrous sulfate, which is a form of iron. The tablets are formulated for prolonged-release, which is designed to help with absorption. Regulatory documents list ferrous sulfate as the main component used for treating iron deficiency.


Q: What should I do if I forget to take a dose of Tardyfer?

Official product information states that if a dose of Tardyfer is missed, patients should continue with the next scheduled dose at the usual time. The label advises against taking a double dose to compensate for the missed tablet. Consistent administration is important for effective iron therapy.


How should Tardyfer be stored and disposed of?

Storage and Disposal of Tardyfer

Official regulatory guidelines define specific conditions for storing and disposing of Tardyfer (Ferrous Sulfate) to ensure its stability and safety.

Storage Requirements

Tardyfer must be stored below 25°C (77°F) and kept in its original container to protect it from moisture. It is mandatory to store this medicine out of the sight and reach of children due to the high risk of fatal iron poisoning from accidental overdose.

Disposal Instructions

Expired or unused Tardyfer must not be thrown away via household waste or wastewater. The official procedure requires that the medicine be returned to a pharmacist for disposal in accordance with local environmental regulations. Do not use the product after the expiration date printed on the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tardyfer found in:

A-Z Index: